Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Sarcophilus harrisii isolate:DFT1 1426

ABSTRACT: Cathelicidin-treated Tasmanian devil facial tumour (DFT1) 1426 cells

PROVIDER: PRJNA970848 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24718770_1.fastq.gz	Fastqsanger.gz
	SRR24718770_2.fastq.gz	Fastqsanger.gz
	SRR24718771_1.fastq.gz	Fastqsanger.gz
	SRR24718771_2.fastq.gz	Fastqsanger.gz
	SRR24718772_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

Sarcophilus harrisii

Project description:Tasmanian devil (Sarcophilus harrisii) RNA-seq in imiquimod-treated devil facial tumour 1 (DFT1) cells

| PRJNA416378 | ENA

Sarcophilus harrisii

Project description:Tasmanian devil facial tumour 454 transcriptome

| PRJNA79479 | ENA

Sarcophilus harrisii

Project description:Tasmanian devil genome sequencing project

| PRJNA51853 | ENA

Sarcophilus harrisii

Project description:The Tasmanian devil is an endangered carnivorous marsupial

| PRJNA51891 | ENA

Tasmanian Devil Facial Tumour Disease - Imiquimod treatment of DFT1 cells

Project description:A Tasmanian Devil Facial Tumour Disease (DFTD) tumor cell line was treated with the drug Imiquimod

2018-04-12 | PXD007135 | Pride

Tasmanian devil facial tumour-derived extracellular vesicles reveal mesenchymal transition markers and adhesion molecules related to metastasis.

Project description:The iconic Tasmanian devil (Sarcophilus harrisii) is endangered due to the transmissible cancer Devil Facial Tumour Disease (DFTD), of which there are two genetically independent subtypes (DFT1 and DFT2). While DFT1 and DFT2 can be differentially diagnosed using tumour biopsies, there is an urgent need to develop less invasive biomarkers that can detect DFTD and distinguish between subtypes. Extracellular vesicles (EVs), the nano-sized membrane-enclosed vesicles present in most biofluids, represent a valuable resource for biomarker discovery. Here, we characterized the proteome of EVs from cultured DFTD cells using data independent acquisition mass spectrometry and an in-house spectral library of >1,500 proteins. EVs from both DFT1 and DFT2 cell lines expressed higher levels of proteins associated with focal adhesion functions. Furthermore, hallmark proteins of epithelial mesenchymal transition were enriched in DFT2 EVs relative to DFT1 EVs. These findings were validated in clinical samples, revealing that the mesenchymal marker tenascin-C was also enriched in EVs derived from the serum of devils infected with DFT2 relative to those infected with DFT1 and healthy controls. This first EV-based investigation of DFTD increases our understanding of the cancers’ EVs and their possible involvement in DFTD progression, such as metastasis. Finally, we demonstrated the potential of EVs to differentiate between DFT1 and DFT2 that highlights their potential use as less invasive liquid biopsies for the Tasmanian devil and other animals.

2024-05-22 | PXD025579 | Pride

Two of a kind: Transmissible Schwann cell cancers in the endangered Tasmanian devil.

Project description:Devil facial tumour disease 1 and 2 (DFT1 and DFT2) are two genetically distinct transmissible cancers endangering the survival of the Tasmanian devil (Sarcophilus harrisii). DFT1 first arose from a cell of the Schwann cell lineage, however, the tissue-of-origin of the recently discovered DFT2 cancer remains unknown. Here we have performed mRNA and protein expression analyses to show that variation in expression patterns between DFT1 and DFT2 tumours is low. Furthermore, DFT2 cells express a range of markers associated with Schwann cell differentiation, suggesting a similar tissue-of-origin to DFT1 tumours. These findings suggest that devils may be predisposed to transmissible cancers of Schwann cell origin. The emergence of these two unique cancers presents an unprecedented opportunity to gain insight into cancer development in animal species.

2019-08-06 | PXD011209 | Pride

Sarcophilus harrisii

Project description:Sarcophilus harrisii and Devil facial tumor disease Raw sequence reads

| PRJNA641648 | ENA

Passage of transmissible cancers in the Tasmanian devil is due to a dominant, shared peptide motif and a limited repertoire of MHC-I allotypes

Project description:Transmissible cancers are spread via the passage of malignant cells. The survival of the Tasmanian devil, the largest marsupial carnivore, is threatened by two independent transmissible cancers, devil facial tumour (DFT) 1 and devil facial tumour 2 (DFT2). To aid the development of a peptide vaccine and to interrogate how histocompatibility barriers can be overcome, we analysed the peptides bound to Major Histocompatibility Complex class I molecules from the Tasmanian devil and its transmissible tumours.

2021-02-08 | PXD020614 | Pride

Sarcophilus harrisii

Project description:Sarcophilus harrisii and devil facial tumor disease Raw RNA-seq reads

| PRJNA693818 | ENA